Insider Information: Nexstim Plc’s offering for an EUR 750,000 convertible bond has closed and EUR 650,000 of the bond was subscribed for
June 25 2024 - 2:30AM
Insider Information: Nexstim Plc’s offering for an EUR 750,000
convertible bond has closed and EUR 650,000 of the bond was
subscribed for
Company Announcement, Helsinki, 25 June 2024 at 9:30 AM
(EEST)
Insider Information: Nexstim Plc’s offering for an EUR
750,000 convertible bond has closed and EUR 650,000 of the bond was
subscribed for
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND,
AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER
JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL.
Nexstim Plc (NXTMH:HEX) announces that its offering for an EUR
750,000 convertible bond has been closed.
The convertible bond has been subscribed for a total amount of
EUR 650,000 by the following parties: Leena Niemistö through
Kaikarhenni Oy, Ossi Haapaniemi through Kalksten Finance Oy, Kyösti
Kakkonen through Joensuun Kauppa ja Kone Oy, and Tero Weckroth
through WRCC Invest Oy.
The complete terms and conditions are attached to this
announcement as Annex 1.
Further information is available on the website
www.nexstim.com, or by
contacting:
Mikko Karvinen, CEO+358 50 326
4101mikko.karvinen@nexstim.com
The Company’s Certified Advisor is Carnegie Investment Bank AB
(publ).
About Nexstim Plc
Nexstim is a Finnish, globally operating
growth-oriented medical technology company. Our mission is to
enable personalized and effective diagnostics and therapies for
challenging brain diseases and disorders.
Nexstim has developed a world-leading
non-invasive brain stimulation technology for navigated
transcranial magnetic stimulation (nTMS) with highly sophisticated
3D navigation providing accurate and personalized targeting of the
TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on
commercialization of the Navigated Brain Stimulation (NBS) system.
The NBS System 5 is the only FDA cleared and CE marked navigated
TMS system for pre-surgical mapping of the speech and motor
cortices of the brain.
Nexstim’s Therapy Business markets and sells the
NBS System 6 which is FDA cleared for marketing and commercial
distribution for the treatment of major depressive disorder (MDD)
in the United States. In Europe, the NBS 6 system is CE marked for
the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North
Growth Market Finland.
For more information, please visit
www.nexstim.com
Forward-Looking Statements
This company announcement contains
forward-looking statements, including, without limitation,
statements regarding Nexstim’s strategy, business plans and focus.
The words “may”, “will”, “could”, “would”, “should”, “expect”,
“plan”, “anticipate”, “intend”, believe”, “estimate”, “predict”,
“project”, “potential”, “continue”, “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this
announcement are based on management’s current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this announcement, including, without
limitation, any related to Nexstim’s business, operations, supply
chain, strategy, goals and anticipated timelines, competition from
other companies, and other risks described in the Report of the
Board of Directors and Financial Statements for the year ended on
31 December 2023 as well as our other past disclosures. Nexstim
cautions you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made. Nexstim
disclaims any obligation to publicly update or revise any such
statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements. Any
forward-looking statements contained in this announcement represent
Nexstim’s views only as of the date hereof and should not be relied
upon as representing its views as of any subsequent date.
- Nexstim Plc_Company announcement 2_25 June 2024_FINAL_EN
- Annex 1_Convertible Loan 24062024 - FINAL